Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers
Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers
复制标题
DOI：
10.1093/cid/ciab492
复制
发表时间：
2021-08-02
影响因子：
11.8
通讯作者：
Jary, Aude
中科院分区：
文献类型：
--
作者：
Marot, Stephane;Malet, Isabelle;Jary, Aude
人们担心中和抗体 (NAb) 对抗严重急性呼吸综合征冠状病毒 2 变种的效力。尽管针对 VOC202012/01 和 501Y.V2 菌株的 BNT162b2 疫苗引起的 NAb 滴度降低，但 28/29 的医护人员 (HCW) 的 NAb 滴度 >= 1:10。相比之下，2019 年冠状病毒病轻度型 6 个月后，只有 9/15 (60%) 的医护人员表现出可检测到的针对 501Y.V2 毒株的 NAB。
There are concerns about neutralizing antibodies' (NAbs') potency against severe acute respiratory syndrome coronavirus 2 variants. Despite decreased NAb titers elicited by BNT162b2 vaccine against VOC202012/01 and 501Y.V2 strains, 28/29 healthcare workers (HCWs) had an NAb titer >= 1:10. In contrast, 6 months after coronavirus disease 2019 mild forms, only 9/15 (60%) of HCWs displayed detectable NAbs against 501Y.V2 strain.